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ABSTRACT
Periostin (POSTN) is a multifunctional glycoprotein that belongs to the group of extracellular matrix (ECM) proteins. Due 
to the molecular structure, cellular interactions, tissue locations as well functions of POSTN, we realize that its pivotal 
role is organization and regulation of ECM microenvironment. In available databases there is a lack of data summarizing 
current knowledge about POSTN expression in the field of gynecology and obstetrics. We conducted a search in PubMed 
of the National Library of Medicine and Google Scholar. Databases were extensively searched for all original and review 
articles/book chapters published in English until December 2019 and related to periostin expression. All relevant articles 
were reviewed and presented as appropriate.
In the field of POSTN expression there is only one paper evaluating its involvement in cervical cancer cell metabolism and 
only two studies analyzing its myometrial commitment: maintenance during pregnancy and induction of parturition in 
physiology as well control of fibroids biology in pathology. Much more attention has been devoted to the expression of 
described protein in the endometriosis, and above all in ovarian cancer. Finally, a few studies carried out among pregnant 
women were presented. 
In this review study we presented current knowledge about periostin expression in the field of gynecology and obstet-
rics. Many achieved results are interesting and further studies are needed to verify some hypotheses. Structure, signaling 
pathways as well many functions of periostin are well-described. However, as it was clearly shown there is a lot of unknown 
issues which are waiting to be explored. 
Key words: periostin; POSTN; cancer; neoplasm; endometriosis; myoma; leiomyoma; fibroid; gestation; pregnancy; 
miscarriage
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INTRODUCTION
Periostin (POSTN) also called osteoblast-specific factor 2 
(OSF-2) is a multifunctional glycoprotein that belongs to the 
group of extracellular matrix (ECM) proteins. Physiological 
POSTN expression was disclosed in wide variety of normal 
fetal and adult tissue; i.a. embryonic periosteum, periodon-
tal ligament, placenta, cardiac valves, adrenal glands, lung, 
thyroid, stomach, colon, vagina, ovary, testis, prostate, and 
breast. It has been shown to be an important regulator of 
bone and tooth formation and maintenance, and cardiac de-
velopment and healing [1, 2]. Additionally, it was also found 
that POSTN is expressed in tissues under stress conditions, 
such as pressure or volume overload in heart, skeletal muscle 
after injury or cellular response to hypoxia. Moreover, POSTN 
overexpression has been reported for some pathological 
states, i.e. chronic sinusitis, allergic airway inflammation as 
well in many cancer types [1–3]. 
The human POSTN is encoded by gene located on 
chromosome 13q13.3, and has two isoforms (779 and 
836-amino acid protein with a molecular weight of 87 kDa 
and 93.3 kDa, respectively) identified through studies on hu-
man placenta and osteosarcoma cDNA libraries [2]. POSTN 
has an N-terminal signal peptide, a cysteine-rich region, 
four internal homology domains and a carboxyl terminal 
region. There is a typical signal sequence at the N-terminus 
suggesting that it has the potential to be a secreted protein. 
The C-terminus is hydrophilic and can undergo alternative 
splicing at the transcriptional level to form splice variants or 
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isomers of POSTN. It has eight types of homologous isoforms 
in human tissues that are associated with the occurrence of 
specific tumors [1, 3].
POSTN by interaction with the integrins (αvβ3, αvβ5, and 
α6β4) activates the Ilk–PI3K/Akt and focal adhesion kinase 
(FAK)-mediated signaling pathways. It is responsible for ECM 
remodeling, as it controls adhesion processes and biome-
chanical properties of connective tissue (i.a. regulation of 
collagen fibriollogenesis) [4, 5]. It creates an environment 
for angiogenesis and lymphangiogenesis, independent 
proliferation, avoidance of apoptosis and the ability for 
cells to re-enter the cell cycle, which in pathology leads to 
promotion of cancer cell survival, invasion and metastases, 
mostly on basis of epithelial-mesenchymal transition (EMT) 
phenomenon [5, 6]. 
Due to the molecular structure, cellular interactions, 
tissue locations as well functions of POSTN we realize that 
its pivotal role is organization and regulation of ECM mi-
croenvironment. In available databases there is lack of data 
summarizing current knowledge about POSTN expression 
in the field of gynecology and obstetrics. 
Methodology of Data Obtaining and Analysis
We conducted a search in PubMed of the National Li-
brary of Medicine and Google Scholar. Databases were ex-
tensively searched for all original and review articles/book 
chapters published in English until December 2019 and 
related to periostin expression using the following keywords 
(one or in combinations): periostin, POSTN, gynecology, can-
cer, neoplasm, endometriosis, myoma, leiomyoma, fibroid, 
obstetrics, gestation, pregnancy, miscarriage. Moreover, ad-
ditional articles from the reference sections of the reviewed 
articles were searched. Overall, all relevant articles were 
reviewed and presented as appropriate.
Cervix 
In the field of cervical expression of POSTN there 
is only one paper evaluating its involvement in cancer 
cell metabolism. Han et al. investigated human cervical 
cancer samples as well commercial cell lines (HeLa and 
SiHa). They disclosed overexpression of POSTN in studied 
cases. Moreover, they observed that POSTN knockdown in 
tested cell lines significantly decreased cell viability, migra-
tion and invasion, and reduced EMT. Furthermore, POSTN 
knockdown suppressed the activation of Akt/mTOR sign-
aling pathway. In well-designed experiment Han et al. [7] 
demonstrated that of MALAT-1/microRNA‐202‐3/POSTN 
axis regulates cell viability, migration and invasion as well 
EMT of cancer cells via Akt/mTOR signaling pathway. Fur-
ther research would be greatly beneficial, especially due to 
unknown prognostic and predictive value of this protein 
in cervical cancer. 
Endometrium 
The endometrium is composed by two types of cells i.e. 
endometrial stromal cells (ESC) and endometrial epithelial 
cells (EEC) which both may have eutopic (physiological) and 
ectopic (pathological) localization. First study on POSTN 
expression in eutopic endometrium was conducted by Hiroi 
et al. [8] in 2008. A significant increase in POSTN expression 
was observed during mid-proliferative and early secre-
tory phases while during late proliferative, mid-secretory 
and late-secretory phases were decreased. Observations 
strongly correlated with estrogen and progesterone sup-
plementation during the study. Moreover, they disclosed 
increased immunohistochemical (IHC) POSTN expression 
in ESC during early proliferative, mid-proliferative and early 
secretory phases as well in EEC in late secretory phase. The 
authors clearly showed that POSTN expression is controlled 
by ovarian steroid hormones, which may have strong impact 
on physiological pregnancy and pathological processes e.g. 
endometriosis. 
Endometriosis is a chronic inflammatory disease caused 
by ectopic endometrium manifesting itself by recurrent 
pain and infertility in women of reproductive age. Repeated 
tissue injury, repair and subsequent fibrosis are its crucial 
elements. Microscopic image is characteristic and well-de-
scribed, however, due to lack of known etiology as well 
signaling pathways, further studies are needed. Therefore, 
Shen et al. [9] investigated IHC POSTN expression in eutopic 
and ectopic endometrium of women diagnosed with endo-
metriosis. They observed cyclic variation of eutopic stromal 
IHC POSTN expression; stronger in the proliferative than in 
the secretory, similarly to Hiroi’s observations. Moreover, 
Shen et al. found the strongest POSTN expression in ectopic 
endometrium, which suggests involvement of POSTN in the 
pathophysiology of endometriosis. In 2015 Xu et al. [10] 
studied mRNA and protein expression of POSTN in ectopic 
ESC. They disclosed that POSTN enhanced ESC migration, 
invasion as well adhesion due to the Ilk/Akt signaling path-
way. Moreover, they speculated that due to the known 
way of action, POSTN may be a new therapeutic target in 
endometriosis. Based on the above data, Zheng et al. [11] 
decided to verify POSTN expression in EEC and check its 
influence on EMT. They received results concordant with 
those by Xu et al., i.e. POSTN enhanced invasion and migra-
tion abilities of EEC as well as, facilitated the EMT through 
Ilk-Akt signaling pathway. Further studies conducted in 
2018 by Logan et al. [12], investigated molecular pattern of 
EEC and ESC of eutopic endometrium women with endome-
triosis. They performed fluorescence-activated cell sorting 
for paired sibling RNA sequencing and miRNA microarray 
and disclosed 151 and 215 differently expressed genes as 
well 9 and 16 differently expressed miRNAs in ESC and EEC, 
respectively. POSTN was found to be downregulated in ESC. 
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Results of this study may be crucial in perspective of eutopic 
endometrium biology in patients affected by endometriosis 
and their pregnancy expectations. 
Other studies on POSTN expression in endometriosis 
are focused on identification therapeutic approach. Ganieva 
et al. determined whether transcription factor 21 (TCF21) 
is involved in the development of endometriosis as an up-
stream regulatory gene of POSTN [13]. They separately veri-
fied expression of POSTN and TCF21 in different types of 
endometriosis. They disclosed that expression of POSTN 
and TCF21 was absent in normal endometrium of women 
without endometriosis, weakly positive in eutopic endome-
trium of women with endometriosis, moderately positive 
in ovarian endometriosis, and strongly positive in deep 
infiltrating endometriosis. Additionally, usage of siRNA 
against human TCF21 suppressed POSTN expression, as 
well transfection of TCF21 plasmid vector into stromal cells 
of women without endometriosis, which natively expressed 
neither POSTN nor TCF21, resulted in presence of their ex-
pression. In view of the above information, Ganieva et al. 
suggest that TCF21 may be promising therapeutic target 
in endometriosis. 
Myometrium
The myometrial expression of POSTN is described only 
in two studies. Liu et al. [14] analyzed molecular mecha-
nism responsible for balance between maintenance of 
pregnancy and induction of parturition. They compared 
contracted lower uterine segment (LUS) with relaxed uter-
ine fundal myometrium (FUN) to assess transcriptome by 
RNA-sequencing, then RT-PCR and immunoblotting to vali-
date sequencing results. Finally, cell contraction/adhesion 
assays and gene microarrays were used to study the cellular 
functions of identified genes. They disclosed higher levels 
of HoxA13, PTGIS, and POSTN in LUS at term prior to labor. 
The authors stated that regionalization of myometrial func-
tion may be mediated by HoxA13. Liu et al. [15] disclosed 
myometrial function of POSTN in physiology, however it was 
suspected to have its role in pathology. Jamaluddin et al. 
performed proteomic profiling of uterine fibroids to analyze 
ECM protein expression pattern. Using genetic sequencing 
and isobaric tagged-based quantitative mass spectrom-
etry (iTRAQ) they analyzed samples in two main groups: 
MED12 positive and negative mutation (one of the most 
common anomalies in fibroids). They disclosed sets of down 
and upregulated proteins, however regardless MED12 status 
POSTN was significantly upregulated. Performed western 
blotting (WB) and IHC analyses confirmed proteomic ob-
servations. They finally concluded that increased POSTN 
is a hallmark of uterine fibroids regardless MED12 status 
and further studies on up-regulated ECM proteins should 
be performed. 
Ovary
Polycystic ovary syndrome (PCOS) is often diagnosed 
a metabolic disease associated with hormonal imbalance. 
There is growing evidence for links between POSTN expres-
sion and ovarian function. Chen et al. [16] evaluated by 
ELISA POSTN levels and compared it with parameters of 
triglyceride metabolism, chronic inflammation, and insulin 
resistance in PCOS patients. Serum POSTN levels in PCOS 
patients were almost 10 times higher than in controls. They 
discovered also that POSTN positively correlates with body 
mass index (BMI), uric acid, homeostasis model assessment 
of insulin resistance (HOMA-IR), high-sensitive C reactive 
protein (hs-CRP), and negatively with insulin sensitivity in-
dex (ISI). Chen et al. finally concluded that elevated levels 
of POSTN are associated with PCOS. In perspective of inci-
dence of PCOS, presented results and lack of studies, further 
analysis is essential. 
Tumor-specific molecular modifications have their place 
in the management of oncologic patients. POSTN is one of 
the glycoproteins identified to have it role in ovarian cancer 
(OC) [17]. One of the first studies showing overexpression of 
POSTN in OC was presented Gillan et al. in 2002. They con-
cluded that POSTN can increase the motility of the cancer 
cells and their adhesion to the peritoneum via integrins 
αvβ3 and αvβ5. It results in detection of POSTN in the ascites 
of OC patients [18]. In the following studies POSTN proper-
ties were evaluated. Zhu et al. tested POSTN expression by 
cDNA microarray, northern blotting and IHC analyses [19]. 
Subsequently, using retroviral transfection, supported by 
WB and ELISA confirmation, they achieved POSTN expres-
sion in OC cells lines: OVCAR-3 and OV2008. The clinical 
effects of exogenous POSTN expression were assessed in 
orthotopic mouse models. Zhu et al. [19] found that POSTN 
overexpression did not change cell growth rates in vitro; 
however, it significantly promoted intraperitoneal tumor 
metastatic growth in immunodeficient mice, which was as-
sociated with increased tumor angiogenesis and decreased 
tumor cell apoptosis. It stays in line with the study by Choi 
et al. [20], who analyzed association between POSTN ex-
pression and lysophosphatidic acid (LPA), bioactive lipid 
crucial for the initiation and progression of OC. Treatment of 
SKOV-3 and OVCAR-3 cell lines with LPA induced expression 
of POSTN. Additionally, induced POSTN expression was 
abrogated by silencing of the LPA receptor expression 
using shRNA lentivirus. Recombinant POSTN stimulated 
adhesion and invasion of SKOV-3 cells what suggests 
that LPA may be associated with POSTN expression 
in the OC. 
Subsequently, Abbot et al. performed glycotranscrip-
tome comparative analysis of tissue and serum patients with 
OC to identify new specific markers. Selected transcripts 
of restricted glycosyltransferases were verified by lectins, 
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which showed tumor-specific glycosylation changes. The 
authors stated that regarding tested glycoprotein markers, 
thrombospondin and POSTN were overexpressed in OC 
and they can be potentially used to distinguish OC patient 
serum from normal serum [21]. Furthermore, proteomic 
study conducted by Tian et al. was aimed on identification 
glycoproteins useful in proper differentiation of histological 
subtypes of OC. The authors utilizing iTRAQ and WB dis-
closed that POSTN is overexpressed in most subtypes of OC 
and is unsuitable for differentiation. However, Tian et al. [22] 
simultaneously pointed its potential involvement in an early 
stages of OC formation, what may also constitute promising 
therapeutic target. 
There are hypotheses that POSTN cleavage by block-
ing antibody or induced transcriptional gene silencing 
may constitute a highly effective method of treatment. 
Zhu et al. [23] developed neutralizing monoclonal antibody 
against POSTN called MZ-1. They performed their study 
on OC mice model derived from cell line A2780 to verify 
impact of MZ-1 on tumor growth and metastasis. The Au-
thors believed that observed inhibited peritoneal metastasis 
after treatment with MZ-1 was result of specific inhibition 
of anchorage-independent growth and survival of POSTN 
expressing cells as well neutralizing effect of POSTN in-
duced cancer cell migration and invasion. Moreover, in vivo 
administration of MZ-1 resulted in reduction in the number 
of metastasis. 
In the subsequent studies prognostic and predictive 
value of POSTN was verified. Karlan et al. [24] performed 
RNA expression microarrays and Rosetta Similarity Search 
Tool to define sets of genes with potential relevance in OC, 
which finally were identified by array comparative genomic 
hybridization. They pointed out that high-grade serous OC 
patients with POSTN/TGFBI expression have significantly 
shorter overall survival (OS) being potential prognostic 
and therapeutic target. Ryner et al. [25] performed gene 
expression profiling on a discovery set of OCs with clini-
cally well-defined response to chemotherapy as well as on 
an independent validation dataset of OC patients from the 
chemo treatment arm of the ICON7 trial. They defined “re-
active stroma” gene signature that is specifically associated 
with primary chemo resistant tumors. IHC and RNA in situ 
hybridization analyses confirmed POSTN, LOX, and FAP genes 
to be associated with the clinical chemo resistance. Moreo-
ver, treatment with recombinant POSTN promoted ES-2 cell 
to carboplatin and paclitaxel treatment in vitro. Finally, they 
demonstrated that a high POSTN expression level predicts 
shorter progression-free survival (PFS) following first-line 
chemotherapy. In perspective of above observations and 
own study, Lister et al. found that promoter-directed small 
antisense non-coding RNAs can induce transcriptional gene 
silencing of  POSTN what may result in a loss of cellular 
motility. Moreover, they observed that cell motility and 
possibly metastasis can be controlled by transcriptional and 
epigenetic regulation of POSTN [6].
In 2015 Tan et al. [26] presented transcriptomics da-
tabase of human OC, referred to as CSIOVDB which com-
prises 3,431 microarray samples from 48 cohorts of private, 
in-house and public human OC datasets. They observed that 
elevated POSTN expression was characteristic for serous 
OC vs other histotypes, stage II-IV vs I, grade 2–3 vs 1 as 
well tumor resistant or refractory to first line chemothera-
py vs sensitive ones. Moreover, Tan et al. [26] pointed that 
POSTN levels were significantly associated with OS, DFS as 
well showed that it was an independent predictor of PFS. 
Similarly, Sung et al. [27] analyzed microarray datasets and 
therefore performed in vitro study with A2780 cell line. They 
observed that POSTN treatment induced cisplatin resistance 
and activate Akt pathway, while its inhibition by selective 
inhibitor, MK-2206 abolished POSTN-induced Akt activation 
and cisplatin resistance in vitro. Overall, they showed that 
overexpression of stromal POSTN has independent poor 
prognostic value (OS and DFS) and is associated with higher 
percentage of platinum resistance. In 2018 Tang et al. [28] 
disclosed high POSTN levels in ascites OC patients (the 
same as Gillan et al. [18]) which correlated with level of 
CD163 tumor-associated macrophages. The high POSTN 
level and macrophage infiltration were inversely associated 
with relapse-free survival for OC patients. Additionally, with 
techniques described by Zhu and Lister, siRNA of POSTN and 
POSTN neutralizing antibody treatment showed that OC cell 
derived POSTN promoted the recruitment of macrophages 
and modulated their cytokine secretion profile [28]. 
In most up-to date studies, in 2019, Lu et al. [29] gener-
ated biotinylated form of human scFv antibody that targets 
the bisected N-glycans. They validated results in in vitro and 
in vivo studies indicating that obtained antibody may be use-
ful for development diagnostic and therapeutic approaches 
for cancers expressing POSTN. Moreover, Sterzyńska et al. 
[30] investigated POSTN mRNA by RT-PCR and protein ex-
pression in cell lysates and cell culture medium by WB as 
well in cell lines by IF regarding development of chemo-
therapeutic resistance. They disclosed increased expression 
of  POSTN in drug-resistant cells and stated that POSTN 
expression might be associated with the development of 
doxorubicin and methotrexate resistance in the primary 
serous OC cell line. Finally, in 2020 Kujawa et al. [31] analyzed 
expression of POSTN and fibronectin. They disclosed that 
higher expressions of both proteins were associated with 
shorter OS and demonstrated that combined score of fibro-
nectins and POSTN was an independent prognostic factor 
for OS. What is new, Kujawa et al. [31] stated that elevated 
expression of fibronectin and POSTN was more common in 
fallopian cancers than in OC.
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Pregnancy 
It has been shown that molecular processes occurring 
in the cancer cell metastasis are like those observed dur-
ing human implantation. In view of above, ECM proteins 
responsible for cell adhesion allowing cancer cell mainte-
nance may also have an impact on implantation. Therefore, 
Morelli et al. [32] analyzed tissue and serum expression 
of POSTN during pregnancy. They analyzed mRNA and 
protein expression in decidual and trophoblastic tissue 
as well serum protein level in between group of pregnant 
with spontaneous pregnancy loss and planned pregnan-
cy termination. In all analyzed aspects POSTN expression 
was elevated in spontaneous pregnancy loss. The Authors 
speculated that POSTN may be a serum marker of good 
endometrial receptivity, embryo quality and predictive 
for pregnancy evolution. In the other study Freis et al. [33] 
tested by ELISA levels of POSTN in patients who conceived 
by IVF/ICSI and ovarian stimulation and with known first 
trimester outcome. They disclosed that increased levels 
of POSTN where observed in early pregnancy in patients 
with following miscarriage in contrast to patients with 
ongoing pregnancy who demonstrated decrease in POSTN 
levels. They hypothesized that POSTN is potential promising 
marker for assessment of pregnancy outcome [33]. Both 
presented studies have consistent results, however, their 
serious limitations are small study groups which should be 
expanded to strengthen conclusions. 
In an interesting paper, Song et al. [34] presented pro-
teomic analysis of neonatal umbilical cord serum. They 
disclosed differences in protein expression between fetal 
gender. They concluded that POSTN expression is consist-
ent with the marked rate of growth and development of 
the fetus. Moreover, they identified 61 neonatal specific 
proteins that were absent in the adult plasma proteome, 
i.a. POSTN. It seems contrary to the results of many other 
research teams, who demonstrated presence of POSTN 
in adults’ sera. Song et al. [34] analyzed arterial umbilical 
blood obtained during vaginal term delivery. Placental 
ablation may potentially influence the POSTN level so at 
least venous umbilical blood should be checked. Option-
ally, blood from cordocentesis would be particularly useful 
for comparative study. The results should also be analyzed 
bearing in mind the study by Sasaki et al. [35] in 2002 who 
speculated POSTN role in the pathogenesis of preeclamp-
sia. They tested blood by novel sandwich chemilumines-
cence assay as well as placenta by using RT-PCR and in situ 
hybridization of preeclampsia and normotensive pregnant 
women. They found elevated serum POSTN levels and its 
increased expression in placental stromal cell. The authors 
hypothesized that serum POSTN might be a novel marker 
of preeclampsia in mechanism of release from the placenta 
due to disturbed adhesive interactions between cells or 
as an element of inflammatory process connected with 
activation of leukocytes and endothelial cells. The exact 
function of POSTN remains unclear, but the fact that it is 
an adhesion molecule in view of achieved results suggest 
novel mechanisms in preeclampsia.
Regarding known functions and interactions of POSTN 
there are some potential clinical implications which should 
be evaluated. Dobreva et al. [36] decided to investigate 
bone morphogenetic protein (BMP) target genes, putative 
amniotic membrane markers in mouse. There is evidence 
that deficiency in one of several components of the BMP 
signaling cascade in mice resulted in defective develop-
ment of the early amnion. In comparative gene expression 
analysis of acknowledged target genes for BMP in different 
extraembryonic tissues, they disclosed by in situ hybrid-
ization POSTN mRNA enrichment in amnion throughout 
gestation. The Authors suggested usage of POSTN and pro-
tein AP-2 as a transcriptional signature for different mouse 
extraembryonic tissues. Until now, no human studies were 
conducted. Moreover, Ivancsó et al. [37] performed a study 
analyzing plasma levels of POSTN in pregnant women with 
asthma, as there is already strong evidence that POSTN 
is a useful biomarker in asthmatic patients. The authors 
stated that POSTN correlates with lung function in asth-
matic pregnancy and it may play role in a normal gestation 
but should be handled with caution in pregnant women 
due to the possible influence of pregnancy on its plasma 
levels. Additionally, Świrska et al. [38] prepared very com-
prehensive review on selected cytokines and hormones of 
confirmed or possible role in pathogenesis of gestational 
diabetes mellitus. They cautioned about substantial facts, 
i.e. known relation between POSTN concentration and 
metabolic diseases as POSTN enhances c-Jun N-terminal 
kinase-dependent suppression of fatty acids oxidation in 
the liver and enhanced POSTN expression by higher glucose 
concentrations. Moreover, they showed many annotations 
in the literature which point to the possible involvement 
of POST in gestational diabetes mellitus. However, surpris-
ingly and sadly in available databases there is lack of studies 
analyzing mentioned above possible relationship. 
CONCLUSIONS 
In this review study we presented current knowledge 
about periostin expression in the field of gynecology and 
obstetrics. Many achieved results are interesting and further 
studies are needed to verify some hypotheses. Structure, 
signaling pathways as well many functions of periostin are 
well-described. However, as it was clearly shown there is 
a lot of unknown issues which are waiting to be explored. 
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